TY - JOUR
T1 - Longitudinal stability of salivary microRNA biomarkers in children and adolescents with autism spectrum disorder
AU - Levitskiy, David
AU - Confair, Alexandra
AU - Wagner, Kayla E.
AU - DeVita, Samantha
AU - Shea, Nicole
AU - McKernan, Elizabeth P.
AU - Kopec, Justin
AU - Russo, Natalie
AU - Middleton, Frank A.
AU - Hicks, Steven D.
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/7
Y1 - 2021/7
N2 - Background: Autism spectrum disorder (ASD) is a complex neurological condition with increasing prevalence. Few tools accurately predict the developmental trajectory of children with ASD. Such tools would allow clinicians to provide accurate prognoses and track the efficacy of therapeutic interventions. Salivary RNAs that reflect the genetic-environmental interactions underlying ASD may provide objective measures of symptom severity and developmental outcomes. This study investigated whether salivary RNAs previously identified in childhood ASD remain perturbed in older children. We also explored whether RNA candidates changed with therapeutic intervention. Method: A case-control design was used to characterize levels of 78 saliva RNA candidates among 96 children (48 ASD, 48 non-ASD, mean age: 11 years). Thirty-one children (22 ASD, 9 non-ASD developmental delay, mean age: 4 years) were followed longitudinally to explore changes of RNA candidates during early intervention. Saliva RNA and standardized behavioral assessments were collected for each participant. Associations between candidate RNAs and behavioral scores were determined in both groups via Spearman Correlation. Changes in candidate RNAs across two time-points were assessed in the younger cohort via Wilcoxon rank-sum test. Results: Seven RNAs were associated with VABS-II and BASC scores in the older group ([R] >0.25, FDR < 0.15). Within the younger cohort, 12 RNAs displayed significant changes over time (FDR < 0.05). Three microRNAs were associated with behavioral scores and changed over time (miR-182−5p, miR-146b-5p, miR-374a-5p). Conclusion: Several salivary RNAs are strongly associated with autistic behaviors in older individuals with ASD and change as early as three months after therapy initiation in younger children. These molecules could be used to track treatment effectiveness and provide prognoses. Further validation is necessary.
AB - Background: Autism spectrum disorder (ASD) is a complex neurological condition with increasing prevalence. Few tools accurately predict the developmental trajectory of children with ASD. Such tools would allow clinicians to provide accurate prognoses and track the efficacy of therapeutic interventions. Salivary RNAs that reflect the genetic-environmental interactions underlying ASD may provide objective measures of symptom severity and developmental outcomes. This study investigated whether salivary RNAs previously identified in childhood ASD remain perturbed in older children. We also explored whether RNA candidates changed with therapeutic intervention. Method: A case-control design was used to characterize levels of 78 saliva RNA candidates among 96 children (48 ASD, 48 non-ASD, mean age: 11 years). Thirty-one children (22 ASD, 9 non-ASD developmental delay, mean age: 4 years) were followed longitudinally to explore changes of RNA candidates during early intervention. Saliva RNA and standardized behavioral assessments were collected for each participant. Associations between candidate RNAs and behavioral scores were determined in both groups via Spearman Correlation. Changes in candidate RNAs across two time-points were assessed in the younger cohort via Wilcoxon rank-sum test. Results: Seven RNAs were associated with VABS-II and BASC scores in the older group ([R] >0.25, FDR < 0.15). Within the younger cohort, 12 RNAs displayed significant changes over time (FDR < 0.05). Three microRNAs were associated with behavioral scores and changed over time (miR-182−5p, miR-146b-5p, miR-374a-5p). Conclusion: Several salivary RNAs are strongly associated with autistic behaviors in older individuals with ASD and change as early as three months after therapy initiation in younger children. These molecules could be used to track treatment effectiveness and provide prognoses. Further validation is necessary.
UR - http://www.scopus.com/inward/record.url?scp=85105605519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105605519&partnerID=8YFLogxK
U2 - 10.1016/j.rasd.2021.101788
DO - 10.1016/j.rasd.2021.101788
M3 - Article
C2 - 34025747
AN - SCOPUS:85105605519
SN - 1750-9467
VL - 85
JO - Research in Autism Spectrum Disorders
JF - Research in Autism Spectrum Disorders
M1 - 101788
ER -